We have developed a highly multiplexed quantitative ChIP-seq technology (hmqChIP-Seq) as a powerful platform allowing to assay a comprehensive set of epigenetic markers (namely histone posttranslational modifications (hPTMs) and other marks including and beyond DNA methylation). With our platform hmqChIP-Seq, 96 or more drug conditions can be screened against 24 or more epigenetic modification markers, such as histone or DNA PTMs using specific antibodies and next-generation sequencing readout.
CancerAddressing target audiences and expressing needs
- Business partners – SMEs, Entrepreneurs, Large Corporations
- Expanding to more markets /finding new customers
- Venture Capital
Partners in drug development and pharmaceutical industry for pilot studies
- Other Actors who can help us fulfil our market potential
- Research and Technology Organisations
- Private Investors
R&D, Technology and Innovation aspects
Tested in laboratory environment -> to be validated in pilot experiments with partners in Pharma
Scalable service laboratory and technology licensing
Drug discovery and development is expensive, slow and risky, especially in oncology, with ineffective preclinical toxicology screening being a significant bottleneck. EpiQure provides a solution for monitoring epigenetic (side) effect of drugs through the entire drug development pipeline
